Issue link: http://osercommunicationsgroup.uberflip.com/i/709455
C h a i n D r u g s t o r e D a i l y 1 9 M o n d a y, A u g u s t 8 , 2 0 1 6 AMNEAL EXPANDS INFRASTRUCTURE, CAPACITY In the past year, Amneal has invested heavily in expanding its manufacturing and packaging capacity, both in the U.S. and abroad. These infrastructure invest- ments will enable the company to signif- icantly increase capacity by the end of 2016, satisfying the production needs of its sizable pipeline across several new dosage forms, including intravaginal tablets, injectables, nasal sprays, topicals, inhalers and transdermals. Currently, Amneal owns a total of nine U.S. FDA-compliant facilities glob- ally, with another three in the queue for inspection. The company spent approxi- mately $350 million in 2015 on capital investments, research and development and acquisitions, all of which are fueling rapid expansion. Amneal has taken its manufacturing capacity from one to two million square feet in the last two years. Amneal is also expanding its global commercial presence and has uncovered opportunities to bolster its total infra- structure/capacity. The company now has a commercial presence in Australia, the U.K., Netherlands, Scandinavia, Germany and Spain, with its internation- al headquarters in Switzerland. Most of these foreign entities were acquisitions of companies with established front-end market presence and product lines, which will continue to grow by incorporating the Amneal label into their product portfolio. Amneal's expansion in India includes R&D, API for self-con- sumption and manufacturing capabilities to accommodate increased production for the international markets, as well as to meet incremental U.S. demand. Most recently, in 2015, Amneal pur- chased the former Johnson & Johnson facility in Cashel, Ireland, which is in Tipperary County in the southeast region of the country. The facility will be dedi- cated to R&D and the commercial pro- duction of metered dose and dry powder inhalers, as well as hormonal injectables and biosimilars – all high-end specialty medications. Once inspected and on-line, the facility will be the 10th U.S. FDA- approved site for Amneal. As Amneal continues its steady growth, it remains steadfastly com- mitted to its core guideline of doing so smartly, in a way that aligns with the company's overall strategy and not simply for the sake of growth. "Amneal will never compromise quality for profit. This commitment to quality stems from our guiding princi- ple to view the consumer of our prod- ucts like a family member," says Jim Luce, Executive Vice President, Sales and Marketing. "This belief permeates throughout the organization, instilling great confidence among our cus- tomers." Visit Amneal at booth #308. For more information, go to www.amneal.com. LUPIN PHARMACEUTICALS: SUPPORTING ADHD PATIENTS Attention-Deficit Hyperactive Disorder is a behavioral disorder defined by symp- toms such as inattentiveness and hyper- activity. Children with ADHD may be prone to careless mistakes, be easily dis- tracted and forgetful. They may have trouble sitting still or staying quiet. These behavioral problems can become chal- lenges for patients, their families and their teachers. Due to educational efforts on the part of government organizations, not- for-profit advocacy groups and pharma- ceutical companies, the general public and the medical community is becoming more aware of this common condition. In an analysis of parent-reported data, the National Health Interview Survey (NHIS) 2011-2013 found that 9.5 percent of children ages 4-17 years have been diagnosed with ADHD. That's 13.3 per- cent of boys and 5.6 percent of girls in this age group in the United States. ADHD diagnosis increased from 7.0 per- cent in 1997-1999 to 10.2 percent in 2012-2014. More than 75 percent of these children will have symptoms as adults. As part of a large and growing glob- al pharmaceutical company with a strong focus on specialty products, Lupin Pharmaceuticals, Inc. is committed to helping ADHD patients manage their condition. With U.S. headquarters in Baltimore, the company delivers high-quality, brand- ed and generic medications trusted by healthcare profes- sionals and patients. "When children are diagnosed with ADHD, it's important that parents and care providers have access to affordable and effective treatments. That's why we're focused on developing new and improved therapies in ADHD treatment and management, and ensuing they are accessible to patients," noted Jay Liska, Lupin's Director of Marketing for Specialty Products. "We also offer a vari- ety of educational materials for ADHD patients, their families and healthcare providers." Lupin works with pedi- atric psychiatrists and pedia- tricians across the country to help care for the growing population of ADHD patients and their families. The company is also a spon- sor of Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), a non-profit organi- zation dedicated to improving the lives of people with ADHD. Lupin continues to strive for excel- lence in supporting ADHD patients, their families and healthcare professionals with affordable, effective medications and helpful educational resources. Visit Lupin Pharmaceuticals at booth #824. For more information, go to www.lupinpharmaceuticals.com. WORKING WITH HOSPITALS TO REDUCE READMISSIONS, PENALTIES The problem: according to studies in the New England Journal of Medicine, 20 percent of high-risk patients are readmit- ted to the hospital within 30 days, and 34 percent of high-risk patients are readmit- ted within 90 days. Stemming readmis- sions is a bottom-line issue for health systems, and a challenge, because until now, there has never been a practical way to follow up with patients after they're discharged. The solution: MarkeTouch Media has launched its proprietary Care Coordination Suite of technology, which seamlessly connects pharmacies and health systems to minimize hospital read- missions and drive patient outcomes. MarkeTouch's platform bridges the gap between what happens when patients leave the hospital with their discharge prescriptions and what happens when they get home. The Care Coordination platform initiates and maximizes ongo- ing, interactive contact with patients pre- dictably and reliably, using proven communi- cation channels. This regular contact enables quick, efficient and automatic communication of patient sta- tus updates and additional risk factors back to the hospital. The initial pilot of MarkeTouch's Care Coordination tech- nology showed significant reduction in readmissions of patients with communi- ty-acquired pneumonia, as well as reduc- tion in readmissions after cardiac events. Over more than a decade, MarkeTouch Media has established a solid track record of designing and implementing innovative pharmacy solu- tions, built on a dependable platform that's customized to meet client goals and includes robust reporting capabilities. All solutions are hosted, requiring no additional hard- ware or software, allowing pharmacies to implement state-of-the-art technology solutions without investing in costly infrastructure. MarkeTouch's exception- ally knowledgeable staff employs indus- try best practices to deliver this technolo- gy to clients and their patients. Visit MarkeTouch Media at booth #421. For more information, go to www.rxtouch.com. CAMBER'S ANTI-RETROVIRAL COMMITMENT RUNS DEEP Camber's parent company, Hetero Drugs, is one of the world's largest producers of anti-retroviral (ARV) finished formula- tions and APIs. The company's commit- ment to HIV/AIDS treatment started way back in 1997, being the first company to develop affordable APIs for anti-retrovi- ral finished formulations. Today, it is rec- ognized as a world leader in providing HIV/AIDS treatment. Approximately 4.5 million HIV/AIDS patients receive ARV formu- lations manufactured by Hetero in its USFDA and WHO approved facilities. Besides the finished formulations, Hetero also supplies APIs to several finished dosage manufacturing companies con- tributing to treatment of an additional 7,000,000 patients worldwide. This means that about one third of the total 11.5 million HIV/AIDS patients under treatment are using API and formulations produced by Hetero. Increased R&D and Manufacturing Facilities Hetero is committed to increasing R&D and manufacturing capacities to meet the demands of the mil- lions of patients that are still deprived of access to treatment. Today, Hetero has built a strong product portfolio of more than 30 ARV combinations and has been offering them to patients at an affordable cost. In order to ensure greater access to life-saving medicines, Hetero has also entered into licensing agreements with innovator companies. This has enabled it to manufacture and market newly launched drugs and combination therapies to expand access to better and newer treat- ment options in developing countries. It works with Ministries of Health and inter- national aid agencies like UNICEF, PAHO, CHAI, IDA Foundation and WHO in order to make medicines available to patients who are in need. Kon Ostaficiuk, President of Camber Pharmaceuticals, had this to say about Hetero's commit- ment to anti-retroviral medications: "Our Chairman B.P.S.Reddy of Hetero Drugs likes to remind us that we are in the life- saving business, and we believe not only in the survival of our patients but also in a superior quality of life." Visit Camber Pharmaceuticals at booth #817. For more information, call 732.529.0430 or go to www.camber pharma.com.